CDC guidance on masking unchanged as Delta variant sweeps U.S. - Walenksy



By Carl O'Donnell and Jeff Mason

July 22 (Reuters) - The U.S. Centers for Disease Control and Prevention has not revised its masking guidance, even as the infectious Delta variant of COVID-19 continues to sweep the United States, driving up case counts, CDC director Rochelle Walensky said during a Thursday press call.

Walensky declined to say if the CDC is considering changing the guidance. The CDC in May relaxed its guidance so that fully vaccinated people do not need to wear masks in most public spaces.

Her comments come a day after U.S President Joe Biden said that the CDC is likely to advise unvaccinated children to wear masks in school as districts around the country prepare to reopen for the coming school year.

The seven-day average of new cases in the United States is up 53% over the previous week, Walensky said. The Delta variant, which was first found in India, now comprises more than 80% of new cases nationwide and has been detected in more than 90 countries.

Some hospitals around the United States are reaching their capacity limits as cases of COVID-19 continue to surge, Walensky said on the call.

The uptick in cases is concentrated in regions of the United States with lower vaccination rates. Florida, Texas and Missouri account for 40% of all new cases nationwide, with around 1 in 5 of all new U.S. cases occurring in Florida, White House COVID-19 task for director Jeffrey Zients said.

Zients said that the United States will continue to distribute tens of millions of COVID-19 vaccines around the world.

The White House in June announced plans to distribute around 80 million COVID-19 vaccines globally.

Top U.S. infectious disease expert Anthony Fauci said there is no reason for people who received Johnson & Johnson's JNJ.N COVID-19 vaccine to assume that they need to get an additional shot of Pfizer Inc's PFE.N or Moderna Inc's MRNA.O vaccines to protect themselves against new variants.

The CDC and U.S. Food and Drug Administration are reviewing data to see if there is waning immunity in vaccinated people to determine if additional booster shots are needed.
Reporting by Carl O'Donnell in New York and Jeff Mason and Lisa Lambert in Washington D.C., Editing by Franklin Paul and Marguerita Choy

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.